TUPE round-up: Mr G Allen and Others v Morrisons Facilities Services Ltd; and more
In the case of Mr G Allen and Others v Morrisons Facilities Services Ltd, the EAT was asked to consider whether employees could bring a claim directly against a new employer to whom their employment had transferred under TUPE, in connection with a failure to inform and consult.
The EAT concluded that they could not.
It is well known that the transferee employer is obliged to provide the transferor with information relating to ‘measures’ it proposes to take in relation to the employees, as part of the consultation process. It is also well known that a transferee can also be jointly and severally liable for a transferor’s failure to inform and consult…
Click on the link below to read the rest of the Wragge Lawrence Graham & Co briefing.
Sign in or Register to continue reading this article
It's quick, easy and free!
It takes just 5 minutes to register. Answer a few simple questions and once completed you’ll have instant access.Register now
Why register to The Lawyer
In-depth, expert analysis into the stories behind the headlines from our leading team of journalists.
Identify the major players and business opportunities within a particular region through our series of free, special reports.
Receive your pick of The Lawyer's daily and weekly email newsletters, tailored by practice area, region and job function.
More relevant to you
To continue providing the best analysis, insight and news across the legal market we are collecting some information about who you are, what you do and where you work to improve The Lawyer and make it more relevant to you.
News from Wragge Lawrence Graham & Co
News from The Lawyer
Briefings from Wragge Lawrence Graham & Co
Ruling on an application for specific disclosure could have big implications in the early stages of procurement disputes.
Hospira v Genentech III: Swiss form claim obvious in view of paper reporting the existence of Phase III trial
Arnold J has delivered the latest blow in the ongoing saga surrounding trastuzumab (the monoclonal antibody in Herceptin) and Hospira’s continued efforts to knock out Genentech’s patents.